Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Cardiology Reports
Published in: Current Cardiology Reports 8/2016

01-08-2016 | Invasive Electrophysiology and Pacing (EK Heist, Section Editor)

Catheter Ablation as First-Line Therapy for Atrial Fibrillation: Ready for Prime-Time?

Authors: Aldo G. Carrizo, Carlos A. Morillo

Published in: Current Cardiology Reports | Issue 8/2016

Login to get access

Abstract

Current guidelines include atrial fibrillation (AF) catheter ablation as part of the management strategy in patients that have failed at least one oral antiarrhythmic drug treatment course. However, growing evidence derived from both randomized and non-randomized studies demonstrate lower rates of AF recurrence and AF burden in patients with paroxysmal AF that are naïve to antiarrhythmic drug treatment. Furthermore, progression from paroxysmal AF to persistent AF appears to be delayed by early catheter ablation of AF. The current review addresses the question of the best timing for ablation in patients with paroxysmal AF and provides the rationale for offering AF ablation as first-line therapy based on the most updated evidence available.
Literature
1.
Magnani JW, Rienstra M, Lin H, et al. Atrial fibrillation: current knowledge and future directions in epidemiology and genomics. Circulation. 2011;124:1982–93.CrossRefPubMedPubMedCentral
2.
Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Heart Rhythm. 2012;9:632–96. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society, e21.CrossRefPubMed
3.
Haïssaguerre M, Jaïs P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339:659–66.CrossRefPubMed
4.
Camm AJ, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719–47.CrossRefPubMed
5.
January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071–104.CrossRefPubMed
6.
de Vos CB, Pisters R, Nieuwlaat R, et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol. 2010;55:725–31.CrossRefPubMed
7.
Kerr CR, Humphries KH, Talajic M, et al. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. Am Heart J. 2005;149:489–96.CrossRefPubMed
8.
Bunch TJ, May HT, Johnson DL, et al. Increasing time between first diagnosis of atrial fibrillation and catheter ablation adversely affects long-term outcomes. Heart Rhythm. 2013;10:1257–62.CrossRefPubMed
9.•
Marrouche NF, Wilber D, Hindricks G, et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. JAMA. 2014;311:498–506.CrossRefPubMed
10.•
Walters TE, Nisbet A, Morris G, et al. Progression of atrial remodeling in patients with high-burden atrial fibrillation: implications for early ablative intervention. Heart Rhythm. 2016;13:331–9. This paper provides evidence that AF progression and atrial remodeling is linked to AF burden in humans. Notably, AF progression was less common with catheter ablation than with antiarrhythmic drugs.CrossRefPubMed
11.
Ausma J, van der Velden HMW, Lenders M-H, et al. Reverse structural and gap-junctional remodeling after prolonged atrial fibrillation in the goat. Circulation. 2003;107:2051–8.CrossRefPubMed
12.
Al-Khatib SM, Thomas L, Wallentin L, et al. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J. 2013;34:2464–71.CrossRefPubMed
13.
Vanassche T, Lauw MN, Eikelboom JW, et al. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J. 2015;36:281–7.CrossRefPubMed
14.
Haïssaguerre M, Jaïs P, Shah DC, et al. Right and left atrial radiofrequency catheter therapy of paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol. 1996;7:1132–44.CrossRefPubMed
15.
Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA. 2005;293:2634–40.CrossRefPubMed
16.
Cosedis Nielsen J, Johannessen A, Raatikainen P, et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med. 2012;367:1587–95.CrossRefPubMed
17.
Morillo CA, Verma A, Connolly SJ, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA. 2014;311:692–700.CrossRefPubMed
18.
Nielsen JC, et al. Five-year follow-up in a randomized comparison of catheter ablation and antiarrhythmic drug therapy as first line treatment. Presented at ESC Congress 2015, London.
19.
Khan AR, Khan S, Sheikh MA, Khuder S, Grubb B, Moukarbel GV. Catheter ablation and antiarrhythmic drug therapy as first- or second-line therapy in the management of atrial fibrillation: systematic review and meta-analysis. Circ Arrhythm Electrophysiol. 2014;7(5):853–60.CrossRefPubMed
20.••
Hakalahti A, Biancari F, Nielsen JC, Raatikainen MJ. Radiofrequency ablation vs. antiarrhythmic drug therapy as first line treatment of symptomatic atrial fibrillation: systematic review and meta-analysis. Europace. 2015;17(3):370–8. This is a meta-analysis of the three landmark randomized control trials of catheter ablation as first-line of therapy in AF patients. The paper shows that catheter ablation is associated with 43% of relative risk reduction of AF recurrence compared with antiarrhythmic drugs. After exclusion of RAFT-1 trial (moderate–high risk of bias), catheter ablation was still associated with higher freedom from AF recurrence.CrossRefPubMed
21.
Santangeli P, Di Biase L, Natale A. Ablation versus drugs: what is the best first-line therapy for paroxysmal atrial fibrillation? Antiarrhythmic drugs are outmoded and catheter ablation should be the first-line option for all patients with paroxysmal atrial fibrillation: pro. Circ Arrhythm Electrophysiol. 2014;7(4):739–46.CrossRefPubMed
22.
Walfridsson H, Walfridsson U, Cosedis Nielsen J, et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation: results on health-related quality of life and symptom burden. The MANTRA-PAF trial Europace. 2015;17(2):215–21.PubMed
23.
Cappato R, Calkins H, Chen SA, et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation. 2005;111:1100–5.CrossRefPubMed
24.
Cappato R, Calkins H, Chen SA, et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3:32–8.CrossRefPubMed
25.
Cappato R, Calkins H, Chen SA, et al. Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation. J Am Coll Cardiol. 2009;53:1798–803.CrossRefPubMed
26.
Lee G, Sparks PB, Morton JB, et al. Low risk of major complications associated with pulmonary vein antral isolation for atrial fibrillation: results of 500 consecutive ablation procedures in patients with low prevalence of structural heart disease from a single center. J Cardiovasc Electrophysiol. 2011;22:163–8.PubMed
27.
Dagres N, Hindricks G, Kottkamp H, et al. Complications of atrial fibrillation ablation in a high-volume center in 1,000 procedures: still cause for concern? J Cardiovasc Electrophysiol. 2009;20:1014–9.CrossRefPubMed
28.
Deshmukh A, Patel NJ, Pant S, et al. In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93801 procedures. Circulation. 2013;128:2104–12.CrossRefPubMed
29.
Tanner H, Makowski K, Roten L, et al. Catheter ablation of atrial fibrillation as first-line therapy—a single-centre experience. Europace. 2011;13:646–53.CrossRefPubMed
30.
Inoue K, Murakawa Y, Nogami A, et al. Current status of catheter ablation of atrial fibrillation in Japan: summary of the 4th survey of the Japanese Catheter Ablation Registry of Atrial Fibrillation (J-CARAF). J Cardiol. 2015.
31.
Chen J, Dagres N, Hocini M, et al. Catheter ablation for atrial fibrillation: results from the first European Snapshot Survey on Procedural Routines for Atrial Fibrillation Ablation (ESS-PRAFA) Part II. Europace. 2015;17:1727–32.PubMed
32.
Namdar M, Chierchia GB, Westra S, et al. Isolating the pulmonary veins as first-line therapy in patients with lone paroxysmal atrial fibrillation using the cryoballoon. Europace. 2012;14:197–203.CrossRefPubMed
33.
Hoffmann E, Dorwarth U, Kuck KH, et al. Design and baseline patient characteristics of the prospective, observational, multicenter and multinational cohort study comparing radiofrequency with cryoablation for pulmonary vein isolation in patients with atrial fibrillation—the Freeze Cohort Study. Int J Clin Med. 2014;5:1161–72.CrossRef
34.
Straube F, Dorwarth U, Ammar-Busch S, et al. First-line catheter ablation of paroxysmal atrial fibrillation: outcome of radiofrequency vs cryoballoon pulmonary vein isolation. Europace. 2015. doi:10.​1093/​europace/​euv271.PubMed
35.
Verma A, Cairns JA, Mitchell LB, et al. 2014 focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation. Can J Cardiol. 2014;30:1114–30.CrossRefPubMed
36.
Packer DL, Lee KL, Mark DB, Robb RA, Rosenberg YD. Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial (CABANA, NCT00911508), accessed ClincalTrials.Gov April 5, 2016.
Metadata
Title
Catheter Ablation as First-Line Therapy for Atrial Fibrillation: Ready for Prime-Time?
Authors
Aldo G. Carrizo
Carlos A. Morillo
Publication date
01-08-2016
Publisher
Springer US
Published in
Current Cardiology Reports / Issue 8/2016
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-016-0747-4

Other articles of this Issue 8/2016

Current Cardiology Reports 8/2016 Go to the issue

Echocardiography (JM Gardin, Section Editor)

Echocardiography in the Assessment of Patients with Rheumatologic Diseases

Myocardial Disease (M Patel, Section Editor)

Hypertrophic Cardiomyopathy: New Evidence Since the 2011 American Cardiology of Cardiology Foundation and American Heart Association Guideline

New Therapies for Cardiovascular Disease (KW Mahaffey, Section Editor)

Bioresorbable Stents in PCI

Myocardial Disease (M Patel, Section Editor)

Recent Advances in Cardiovascular Imaging Relevant to the Management of Patients with Suspected Cardiac Amyloidosis

Cardiac PET, CT, and MRI (SE Petersen and F Pugliese, Section Editors)

Aortic Stenosis, a Left Ventricular Disease: Insights from Advanced Imaging

Management of Acute Coronary Syndromes (AS Jaffe, Section Editor)

Revascularization Strategies in Patients with Diabetes Mellitus and Acute Coronary Syndrome